[go: up one dir, main page]

WO2004089313A3 - Nouvelles formes de l'olanzapine et methodes de traitement associees - Google Patents

Nouvelles formes de l'olanzapine et methodes de traitement associees Download PDF

Info

Publication number
WO2004089313A3
WO2004089313A3 PCT/US2004/009947 US2004009947W WO2004089313A3 WO 2004089313 A3 WO2004089313 A3 WO 2004089313A3 US 2004009947 W US2004009947 W US 2004009947W WO 2004089313 A3 WO2004089313 A3 WO 2004089313A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
forms
related methods
novel
olanzapine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/009947
Other languages
English (en)
Other versions
WO2004089313A2 (fr
Inventor
Magali Bourghol Hickey
Julius Remenar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transform Pharmaceuticals Inc
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/fr
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from US10/747,742 external-priority patent/US7790905B2/en
Priority claimed from PCT/US2003/041642 external-priority patent/WO2004060347A2/fr
Priority claimed from PCT/US2004/006288 external-priority patent/WO2004078163A2/fr
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Priority to US10/551,014 priority Critical patent/US20060223794A1/en
Publication of WO2004089313A2 publication Critical patent/WO2004089313A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004089313A3 publication Critical patent/WO2004089313A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne de nouvelles formes solubles de l'olanzapine. Parmi ces formes figurent des sels, des co-cristaux et des solvates de l'olanzapine. Cette invention concerne également de nouvelles compositions pharmaceutiques contenant lesdites nouvelles formes solubles ainsi que des méthodes de traitement associées. Les compositions et méthodes de la présente invention sont utiles dans le traitement de la psychose et de troubles fonctionnels intestinaux.
PCT/US2004/009947 2002-02-15 2004-03-31 Nouvelles formes de l'olanzapine et methodes de traitement associees Ceased WO2004089313A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/551,014 US20060223794A1 (en) 2002-02-15 2004-03-31 Novel olanzapine forms and related methods of treatment

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US45950103P 2003-04-01 2003-04-01
US60/459,501 2003-04-01
US48706403P 2003-07-11 2003-07-11
US48671303P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
US60/486,713 2003-07-11
USPCT/US03/27772 2003-09-04
PCT/US2003/027772 WO2004078161A1 (fr) 2003-02-28 2003-09-04 Compositions co-cristallines pharmaceutiques de medicaments, notamment de carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophene, aspirine, flurbiprofene, phenytoine et ibuprofene
US10/660,202 2003-09-11
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US10/747,742 2003-12-29
USPCT/US03/41642 2003-12-29
US10/747,742 US7790905B2 (en) 2002-02-15 2003-12-29 Pharmaceutical propylene glycol solvate compositions
PCT/US2003/041642 WO2004060347A2 (fr) 2002-09-03 2003-12-29 Compositions pharmaceutiques de solvates de propylene glycol
PCT/US2004/006288 WO2004078163A2 (fr) 2003-02-28 2004-02-26 Compositions pharmaceutiques a base d'un co-cristal
USPCT/US04/06288 2004-02-26
US54834304P 2004-02-27 2004-02-27
US60/548,343 2004-02-27

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
PCT/US2003/019574 Continuation-In-Part WO2004000284A1 (fr) 2002-02-15 2003-06-20 Compositions pharmaceutiques a dissolution amelioree
US10/747,742 Continuation US7790905B2 (en) 2002-02-15 2003-12-29 Pharmaceutical propylene glycol solvate compositions

Publications (2)

Publication Number Publication Date
WO2004089313A2 WO2004089313A2 (fr) 2004-10-21
WO2004089313A3 true WO2004089313A3 (fr) 2005-11-24

Family

ID=33163281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009947 Ceased WO2004089313A2 (fr) 2002-02-15 2004-03-31 Nouvelles formes de l'olanzapine et methodes de traitement associees

Country Status (1)

Country Link
WO (1) WO2004089313A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP1494998A2 (fr) 2002-03-01 2005-01-12 University Of South Florida Phases solides multicomposants contentant au moins un principe pharmaceutiquement actif
MXPA05000232A (es) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
PL377084A1 (pl) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent Nowe związki olanzapiny i sposób ich wytwarzania
WO2008004033A1 (fr) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. Formulation stable d'olanzapine contenant des antioxidants
DE102006032426A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
DE102006032427A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
US8642631B2 (en) 2008-05-27 2014-02-04 University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
US8318807B2 (en) 2010-02-03 2012-11-27 Laurus Labs Private Limited Pterostilbene cocrystals
WO2012114342A1 (fr) 2011-02-23 2012-08-30 Coeruleus Ltd. Complexes de flumazénil, compositions les comprenant et leurs utilisations
CN113200949B (zh) * 2021-04-16 2022-11-29 天津大学 一种二甲胺含笑内酯-水杨酸盐及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703232A (en) * 1995-03-24 1997-12-30 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5736541A (en) * 1995-03-24 1998-04-07 Eli Lilly And Company Olanzapine polymorph crystal form
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703232A (en) * 1995-03-24 1997-12-30 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5736541A (en) * 1995-03-24 1998-04-07 Eli Lilly And Company Olanzapine polymorph crystal form
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine

Also Published As

Publication number Publication date
WO2004089313A2 (fr) 2004-10-21

Similar Documents

Publication Publication Date Title
IL171170A (en) History of itensinoids and their pharmaceutical preparations, methods of preparation and use thereof
WO2004113277A3 (fr) Procedes et compositions de traitement de maladies associees aux amyloides
WO2005046603A3 (fr) Composes pyridiniques
WO2004110357A3 (fr) Composes heterocycliques et leurs utilisations
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2006058236A3 (fr) Composition et methode pour traiter des affections neurologiques
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
EP1583821A4 (fr) Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
WO2004089313A3 (fr) Nouvelles formes de l'olanzapine et methodes de traitement associees
NL1026329A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
WO2004009062A3 (fr) Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
WO2004074232A8 (fr) Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
WO2001049703A3 (fr) Sapogenines substituees et leur utilisation
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
WO2004074243A3 (fr) Heterocyclyl-3-sulfonylindazoles utilises comme ligands de la 5-hydroxytryptamine-6
WO2007143523A3 (fr) Sulfonamides tricycliques condensés inhibiteurs de gamma-secrétase
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
WO2005099702A3 (fr) Derives de r(?)-11-hydroxyaporphines et utilisations de ces derives
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2005105753A3 (fr) Derives naphthalimides, procedes de fabrication et compositions pharmaceutiques les renfermant
WO2004087066A3 (fr) Inhibiteurs de hif-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006223794

Country of ref document: US

Ref document number: 10551014

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10551014

Country of ref document: US